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In an open-label, randomized, multicenter, multiple-dose pharmacokinetic study, we determined the steady-
state pharmacokinetics of amprenavir with and without coadministration of indinavir, nelfinavir, or saquinavir
soft gel formulation in 31 human immunodeficiency virus type 1-infected subjects. The results indicated that
amprenavir plasma concentrations were decreased by saquinavir soft gel capsule (by 32% for area under the
concentration-time curve at steady state [AUCss] and 37% for peak plasma concentration at steady state
[Cmax,ss]) and increased by indinavir (33% for AUCss). Nelfinavir significantly increased amprenavir minimum
drug concentration at steady state (by 189%) but did not affect amprenavir AUCss or Cmax,ss. Nelfinavir and
saquinavir steady-state pharmacokinetics were unchanged by coadministration with amprenavir compared
with the historical monotherapy data. Concentrations of indinavir, coadministered with amprenavir, in plasma
decreased in both single-dose and steady-state evaluations. The changes in amprenavir steady-state pharma-
cokinetic parameters, relative to those for amprenavir alone, were not consistent among protease inhibitors,
nor were the changes consistent with potential interactions in CYP3A4 metabolism or P-glycoprotein transport.
No dose adjustment of either protease inhibitor in any of the combinations studied is needed.
In vivo inhibition of human immunodeficiency virus (HIV)
replication via combination antiretroviral therapy can be
achieved with drugs targeting different HIV enzymes (i.e., re-
verse transcriptase and protease) or with drugs targeting the
same viral enzyme (i.e., reverse transcriptase or protease).
Although the combined use of HIV reverse transcriptase and
protease inhibitors in HIV-infected individuals has been asso-
ciated with significant virologic and clinical benefits (2, 3, 8, 15;
British HIV Association Guidelines for the Treatment of HIV
Disease with Antiretroviral Therapy [http://www.bhiva.org]
and Department of Health and Human Services and Henry J.
Kaiser Family Foundation Panel on Clinical Practices for the
Treatment of HIV Infection, Guidelines for the Use of Anti-
retroviral Agents in HIV-Infected Adults and Adolescents
[http://www.hivatis.org]), the high anti-HIV potency of the pro-
tease inhibitors provides a rationale for examining the clinical
utility of dual protease inhibitor combinations.
The success of a dual protease inhibitor combination ap-
proach, however, may depend on potential drug-drug interac-
tions. All of the currently available HIV protease inhibitors are
metabolized in the liver and gastrointestinal tract, primarily by
the cytochrome P450 system (1). In addition, all protease in-
hibitors are substrates for transport by the P-glycoprotein drug
transport protein (10, 11). The actions of each protease inhib-
itor in a dual combination regimen on the pharmacokinetics of
the partner protease inhibitor must be assessed to determine
whether drug-drug interactions that affect plasma drug con-
centrations will occur and whether two specific protease inhib-
itors can be safely coadministered.
Amprenavir (Agenerase, formerly 141W94) is a potent HIV
protease inhibitor that was originally synthesized using a struc-
ture-based drug design process (9). The mean 50% inhibitory
concentration of amprenavir against 334 HIV clinical isolates
is 29 nM (19). Amprenavir binds to proteins in normal human
plasma or serum to the extent of 90%, with the greatest
degree of binding to 1-acid-glycoprotein (AAG) (89%) and
albumin (42%) (12). The metabolism of amprenavir, like that
of the other approved HIV protease inhibitors, appears to be
primarily dependent upon the 3A4 isozyme of the hepatic
cytochrome P450 system (CYP3A4), based on in vitro and in
vivo studies (6; J. Woolley, S. Studenberg, C. Boehlert, G.
Bowers, A. Sinhababu, and P. Adams, Abstr. 37th Intersci.
Conf. Antimicrob. Agents Chemother., abstr. A-60, 1997).
These and other drug interaction studies have shown that am-
prenavir inhibits CYP3A4 to a degree comparable to that
exhibited by indinavir and nelfinavir.
We report here the steady-state pharmacokinetics of am-
prenavir administered alone and as part of three dual protease
inhibitor combinations with indinavir, nelfinavir, or saquinavir
soft gel capsule (sgc) formulation in protease inhibitor-naı̈ve,
HIV-infected adults (Glaxo Wellcome protocol PROA2001).
The pharmacokinetics of each partner protease inhibitor used
in combination with amprenavir were also assessed and com-
pared with historical monotherapy data for each drug as indi-
cated: nelfinavir (B. Kerr, personal communication), indinavir
(Merck & Co., complete prescribing information for indinavir
[Crixivan]), and saquinavir (16). Preliminary data from this
study have been previously presented (B. M. Sadler, J. Eron, J.
Wakeford, G. Pagano, C. Rawls, J. McCrea, K. Mazina, and
P. J. Deutsch, Abstr. 37th Intersci. Conf. Antimicrob. Agents
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Chemother., abstr. A-56, 1997; B. Sadler, C. Gillotin, G. E.
Chittick, and W. T. Symonds, Abstr. 12th World AIDS Conf.,
abstr. 12389, 1998). This 3-week, phase I trial was part of a
larger 48-week phase I-II study to explore the antiviral effect
and evaluate the long-term safety and tolerability of amprena-
vir-containing dual protease inhibitor therapy (7). The phar-
macokinetic interactions of ritonavir and amprenavir were
studied separately (19).
Study population. The study entry criteria were per the work
of Eron et al. (7). Briefly, subjects were enrolled in the study if
they were 18 years of age and were HIV-seropositive adults
with CD4 cell counts of 200 cells/mm3 and plasma HIV
RNA levels of 10,000 copies/ml. Subjects were excluded from
the study if they had prior treatment with a protease inhibitor
or received any antiretroviral therapy within 2 weeks prior to
enrollment. Subjects with malabsorption, acute opportunistic
infections, or standard laboratory values outside of prespeci-
fied ranges were excluded. Women of childbearing potential
were required to have a negative serum human chorionic -go-
nadotropin test within 7 days of the start of dosing. Prior
antiretroviral therapy (with drugs other than protease inhibi-
tors) was permitted, but subjects were required to discontinue
antiretroviral therapy 2 weeks prior to enrollment. All subjects
provided written informed consent to participate in the study.
All subjects were monitored for clinical adverse experiences
and/or abnormal laboratory test findings throughout the study
period, including the follow-up evaluation.
Study design and drug administration. A single-dose, phase
IA interaction study of amprenavir and indinavir was con-
ducted prior to the start of the 3-week, phase I multiple-dose
study of the dual protease inhibitor combinations. The single-
dose study was carried out to determine the pharmacokinetics
of amprenavir and indinavir when administered in combina-
tion, to assess whether pharmacokinetic interactions exist be-
tween amprenavir and indinavir when administered as a single-
dose combination, and to determine the dose of indinavir to be
used in the later multiple-dose phases (phases I and II) of this
study. Subjects were given a single oral dose of indinavir (800
mg) and amprenavir (800 mg) simultaneously, after an over-
night fast of at least 8 h and 1.5 h before a meal.
This phase I study was an open-label, randomized, multi-
center, multiple-dose trial of amprenavir, alone and in dual
combination with indinavir, nelfinavir, and saquinavir sgc. HIV
type 1 (HIV-1)-positive subjects who met the study entry cri-
teria were enrolled and randomly assigned to one of the fol-
lowing four treatment groups: amprenavir plus indinavir (800
mg), amprenavir plus nelfinavir (750 mg), amprenavir plus
saquinavir sgc (800 mg), or amprenavir alone. All treatments
were administered three times daily, and no concomitant nu-
cleoside therapy was allowed for the first 3 weeks of the study.
Although amprenavir is approved as a twice-daily regimen, it
was administered on a three-times-a-day dosing schedule for
the convenience of the participants (as the partner protease
inhibitors had to be administered as a three-times-a-day med-
ication). Initially, the amprenavir dose was 800 mg but was
reduced to 750 mg during the study secondary to a change in
amprenavir formulation. All but three subjects received the
800-mg dose at the time of their pharmacokinetics evaluation.
At the time of the study, on recommendation of the drug’s
manufacturer, Roche Laboratories, saquinavir sgc was given as
800 mg, rather than the now-approved 1,200 mg, three times
daily. Subjects assigned to receive nelfinavir or saquinavir sgc
were instructed to take both study medications with food;
those assigned to receive indinavir or amprenavir monotherapy
were instructed to take both study medications either 1 h
before or 2 h after a meal. Subjects assigned to receive indi-
navir were also instructed to drink at least 2 liters of water per
day. Subjects were provided with a standard breakfast meal
that consisted of 58 g of carbohydrate, 33 g of protein, and 67 g
of fat.
Subjects were instructed to fast overnight (at least 8 h) from
the evening prior to the scheduled morning dosing and sam-
pling; subjects’ morning dose was to be postponed until arrival
at the clinic for sampling. Although the use of medically nec-
essary concomitant medications was permitted, it was advised
that medications metabolized by CYP3A4 not be used because
of the potential for serious and/or life-threatening adverse
experiences. Such contraindicated medications included ter-
fenadine, astemizole, cisapride, triazolam, midazolam, and
ergotamine- and/or dihydroergotamine-containing regimens.
Chemoprophylactic agents for HIV-related conditions were
permitted. The study protocol was approved by the Institu-
tional Review Board affiliated with each study center.
Plasma sampling. Blood samples were collected on the first
day of dosing to determine the single-dose indinavir and am-
prenavir pharmacokinetic parameters (phase IA) and at the
week 2 study visit to determine steady-state pharmacokinetic
parameters for amprenavir, indinavir, nelfinavir, and saquina-
vir. Blood samples were collected at predose and then at 0.25,
0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, and 8 h postdose. For amprenavir,
blood was collected in EDTA-containing tubes, and for indi-
navir, nelfinavir, and saquinavir sgc, blood was collected in
sodium heparin tubes. All plasma samples were stored frozen
at 20°C until analysis. Plasma sampling for AAG was con-
ducted at weeks 1, 2, and 3.
Safety evaluations. Safety and tolerability were evaluated at
predose; day 1; and weeks 1, 2, 3, and 4 and every 4 weeks
thereafter. Evaluations were conducted by physical examina-
tion, vital signs, electrocardiogram, hematology, clinical chem-
istry, urinalysis, and monitoring for clinical adverse experi-
ences.
Assays for protease inhibitors. Concentrations of amprena-
vir in plasma were determined using cross-validated isocratic
reversed-phase chromatography with fluorescence detection as
previously described (18) and an automated high-performance
liquid chromatography method with detection by tandem mass
spectrometry. Concentrations of indinavir, saquinavir, and
nelfinavir in plasma were analyzed by specific, validated high-
performance liquid chromatography assays (22, 23; document
no. RD1998/01807/00, RD1998/00615/00, and RD1998/01806/
00, Glaxo Wellcome Inc.) with UV detection conducted by the
following laboratories: Oneida Research Services, Whitesboro,
N.Y. (saquinavir); BAS Analytics, West Lafayette, Ind. (indi-
navir); and PPD-Pharmaco, Richmond, Va. (nelfinavir and
M8-nelfinavir). Calibration curves for indinavir in plasma were
linear for the concentration range of 5 to 500 ng/ml. The
intraday precision ranged from 1.8 to 6.3%, the interday pre-
cision was 1.8 to 2.8%, and the interday accuracy ranged from
91.2 to 94.5%. For saquinavir, calibration curves were linear
for the concentration range of 10 to 350 ng/ml. Interday pre-
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cision was 8.62%, and the interday accuracy ranged from 99.88
to 106.38%. Intraday precision was 8.02%, and the intraday
accuracy ranged from 96.66 to 116.18%. The calibration curves
for nelfinavir were linear for the concentration range of 0.05 to
10 g/ml. The intraday precision was 1.53 to 7.21%, and the
intraday accuracy was 16%, while the interday precision was
2.32 to 5.43%, and the interassay accuracy was 9.75%.
Pharmacokinetic analyses. Model-independent pharmaco-
kinetic parameters for single and multiple oral dosing were cal-
culated using WinNonlin Pro, version 1.5 (Scientific Consult-
ing, Inc., Cary, N.C.). The peak plasma concentration (Cmax),
the time to reach peak plasma concentration (Tmax), the peak
plasma concentration at steady state (Cmax,ss), and the time to
reach maximum plasma concentration (Tmax,ss) were observed
from the individual plasma concentration-time data. The min-
imum drug concentration at steady state (Cmin,ss) was calculat-
ed as (C0  Ct)/2, where C0 is the plasma concentration before
the last dose and Ct is the plasma concentration of the last
steady-state dosing interval. The area under the plasma con-
centration-time curve (AUC03t) from the time of the predose
sample to the time of the last sample was calculated using the
linear trapezoidal rule. When necessary, AUC03t was extrap-




to AUC03t, where t is the time of the last plasma concentration
sample during the steady-state dosing interval, z is the elim-
ination rate constant, and 	 is the length of the steady-state
dosing interval. The apparent total clearance (CL/F) was cal-
culated as dose/AUCss.
Statistical analyses. Only descriptive statistical analysis was
performed for phase IA. The mean amprenavir AUC and
mean indinavir AUC038 h and Cmax were compared with their
respective historical control values. The 95% confidence inter-
vals (CI) of the means were calculated and not considered
different from their historical values if the mean used as the
reference fell within the limit of the 95% CI. The single-dose
historical pharmacokinetic data for indinavir monotherapy was
from the work of Yeh et al. (24); that for amprenavir mono-
therapy, in which a single dose of 900 mg was administered,
was from two studies (17, 18). Values obtained from the two
amprenavir studies were recalculated to reflect the AUC038 h
only and normalized to an 800-mg dose for comparison pur-
poses in this study.
AUCss, Cmax,ss, Cmin,ss, and CL/F for all protease inhibitors
were analyzed after logarithmic transformation. Pharmacoki-
netic parameters for subjects who received 750 mg of amprena-
vir were normalized to an 800-mg dose prior to descriptive
summarization and statistical analyses. The pharmacokinetic
parameters of each protease inhibitor in a dual therapy regi-
men were compared to those of each drug administered as a
single agent. For amprenavir, the monotherapy group of this
study was used as the single-agent comparator; for indinavir,
nelfinavir, and saquinavir, historical values were used as the
single-agent comparator. The calculated arithmetic mean or
geometric least squares (GLS) mean values for protease inhib-
itors in combination obtained in this study were considered not
different from single-agent values if the latter values fell within
the limit of the 95% CI.
Analyses of variance, considering treatment as fixed effects,
were performed using the mixed linear model procedure (SAS
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scriptive summary statistics, GLS means, and associated 95%
CI were calculated for each treatment. The ratio of the GLS
means and associated 90% CI for AUCss, Cmax,ss, Cmin,ss, and
CL/F was obtained using two one-sided tests. The analysis of
Tmax,ss was performed using standard nonparametric methods,
and the 95% CI for median Tmax,ss was computed. Treatment
comparison of Tmax,ss was performed using a Wilcoxon rank
sum test. Estimates of the median difference between treat-
ments (combination versus alone for each protease inhibitor)
and associated 90% CI were calculated. An analysis of covari-
ance considering the fixed effects of treatment, race, weight,
age, AAG, albumin, bilirubin, and HIV risk factors (i.e., injec-
tion drug use versus all other risk factors) was performed on
amprenavir pharmacokinetic parameters after log transforma-
tion.
Subject demographics and accountability. This study was
conducted between January 1997 and October 1998 at three
centers in the United States. A total of 34 HIV-infected sub-
jects were enrolled in phase I and randomized to receive study
medication. Of these 34 subjects, 12 (all from one center)
participated in phase IA and all 12 were included in the single-
dose pharmacokinetic analysis. Of the 33 subjects who initiated
study treatment in phase I (one subject randomized to the
amprenavir-alone group withdrew from the study before re-
ceiving the first dose), 31 were included in the multiple-dose
pharmacokinetic analysis. One of the subjects not included in
the analysis withdrew consent at week 3, and the other subject
was lost to follow-up at week 2.
No significant differences in baseline characteristics were
apparent among the treatment groups, and overall, 62% were
white and 76% were male, with the median age being 38 years,
the median CD4 cell count being 393 cells/mm3, and the me-
dian log10 HIV RNA value being 4.74—although the amprena-
vir-saquinavir sgc group had higher percentages of subjects
who were older, black (50%), female (50%) and who reported
heterosexual contact as an HIV risk factor (7). Most subjects
(79%) were asymptomatic (Centers for Disease Control and
Prevention classification A), and only one subject had a diag-
nosis of AIDS (Centers for Disease Control and Prevention
classification C, in the amprenavir-alone group) (4). The ma-
jority of subjects (62%) had received prior antiretroviral ther-
apy.
Single-dose amprenavir-indinavir pharmacokinetic interac-
tions (phase IA). Coadministration of amprenavir and indina-
vir produced an increase in the mean amprenavir AUC038 h
relative to the historical amprenavir monotherapy data: 25.32
versus 21.49 g  h/ml (17, 18) (see Table 1). This change in
mean amprenavir AUC038 h represents an increase of 18%
over that observed for amprenavir alone (18). Coadministra-
tion of amprenavir and indinavir produced a decrease in both
indinavir AUC038 h (35%) and Cmax (23%) compared with
historical indinavir monotherapy data (24). Only the decrease
in indinavir Cmax was statistically different from indinavir con-
trol data (see Table 2).
Phase I safety and tolerability. No serious adverse events
occurred during the study. A full description of the safety
findings is given in the work of Eron et al. (7).
Effect of multiple-dose indinavir, nelfinavir, or saquinavir
sgc on amprenavir pharmacokinetics. The steady-state phar-
macokinetic values obtained for amprenavir in dual combina-
tion with indinavir, nelfinavir, or saquinavir sgc and amprena-
vir alone after multiple oral doses are presented in Table 1.
The GLS mean ratios for AUCss (0.68 [90% CI, 0.51 to 0.91])
and Cmax,ss (0.63 [90% CI, 0.46 to 0.86]) between the saquina-
vir sgc-amprenavir combination and amprenavir alone are sig-
nificantly different, as are the GLS means for AUCss between
the indinavir-amprenavir combination and amprenavir alone,
which increased by 33% (90% CI, 1.02 to 1.73; ratio, 1.33). The
GLS mean ratio for Cmin,ss of the nelfinavir-amprenavir com-
bination was also significantly increased by 2.89-fold (90% CI,
1.52 to 5.48) compared to the amprenavir-alone treatment
group.
Effect of multiple-dose amprenavir on indinavir, nelfinavir,
or saquinavir sgc pharmacokinetics. The steady-state pharma-
cokinetics of indinavir, nelfinavir, and saquinavir, estimated
from subjects treated with each of these protease inhibitors in
dual combination regimens with amprenavir, are presented in
Table 2. Also given in the table are historical values of steady-
state pharmacokinetic parameters for each of the protease
inhibitors administered as monotherapy. Compared with indi-

















SQV  APV 2.58 (0.15–5.01) 1.15 (0.12–2.18) 0.071 (0.01–0.14) 1.0 (0.56–2.18) 12,854 (871–22,837)
Reference value (16) 3.21 0.95 0.14 2 4,237
Ratio 0.81 1.21 0.52 0.68 3.03
IDV  APV 13.63 (10.79–16.47) 7.01 (6.22–7.81) 0.13 (0.09–0.17) 0.75 (0.70–0.98) 1,052 (805–1,298)
Reference valueb 21.85 8.98 0.18 0.80 610
Ratio 0.62 0.78 0.73 1.05 1.72
NFV  APV 20.03 (10.83–29.23) 3.58 (2.10–5.05) 1.70 (0.47–2.93) 3.63 722 (409–1,034)
Reference valuec 17.4 3.18 1.49 —d 718
Ratio 1.15 1.12 1.14 1.00
IDV  APV (single dose) 11.18 (7.63–14.73) 5.50 (3.77–7.24)
Reference value (24) 17.11 7.17
Ratio 0.65 0.77
a Values for pharmacokinetic parameters are means (95% CI), except for Tmax, for which values are medians (nonparametric; 95% CI). SQV, saquinavir; IDV,
indinavir; NFV, nelfinavir; APV, amprenavir.
b Merck & Co., complete prescribing information for indinavir.
c B. Kerr, personal communication.
d —, reference value unavailable.
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navir-alone historical data, amprenavir was found to decrease
the AUCss, Cmax,ss, and Cmin,ss of indinavir by 38, 22, and 27%,
respectively, and to increase the CL/F by 72% (Table 2). The
decreases in indinavir AUCss, Cmax,ss, and Cmin,ss and the in-
crease in CL/F produced by coadministration with amprenavir
were statistically different from historical values (indinavir
alone), as indicated by historical reference values falling out-
side the 95% CI range of the means of these pharmacokinetic
parameters for the indinavir and amprenavir combination.
None of the pharmacokinetic parameter values for either sa-
quinavir sgc or nelfinavir obtained from the historical studies
fell outside the 95% CI range observed in this study.
AAG, treatment, and amprenavir pharmacokinetic param-
eters. Analysis of covariance revealed that, of the factors eval-
uated (AAG, age, albumin, bilirubin, HIV risk factor, race,
treatment, and weight), only serum AAG concentrations and
protease inhibitor coadministration treatment had a statisti-
cally significant effect on amprenavir steady-state pharmacoki-
netic parameters. AAG concentrations significantly influenced
amprenavir AUCss (P 
 0.004) and Cmax,ss (P 
 0.026). Treat-
ment also had a statistically significant effect on amprenavir
AUCss (P 
 0.004) and Cmax,ss (P 
 0.015).
This pharmacokinetic evaluation of amprenavir-containing
dual protease inhibitor regimens compared amprenavir steady-
state pharmacokinetics calculated from subjects receiving am-
prenavir monotherapy with those from subjects receiving am-
prenavir in combination with another protease inhibitor.
Historical monotherapy data for indinavir, nelfinavir, and sa-
quinavir sgc were used as reference values for the steady-state
pharmacokinetics of the partner protease inhibitor in each
combination. The concurrent study design employed was used
to avoid unnecessarily exposing subjects to protease inhibitor
monotherapy (i.e., by a crossover design) which could poten-
tially facilitate the development of drug resistance.
Amprenavir is approved as a twice-daily regimen, but given
the three-times-a-day dosing schedule of the partner protease
inhibitors, amprenavir was instructed to be taken three times
daily in this study to simplify logistics and for the convenience
of the participants. To characterize any drug-drug interactions
after multiple dosing, steady-state pharmacokinetic data for
the individual protease inhibitors in each of the dual protease
inhibitor combinations were compared with the steady-state
data for each protease inhibitor given alone. The decrease in
amprenavir AUCss that occurred when amprenavir was coad-
ministered with saquinavir sgc may prove to be clinically rele-
vant. Several studies of HIV protease inhibitors have shown
that AUCss and Cmin,ss are related to antiviral activity or drug
resistance (4, 5, 13, 14, 21; G. L. Drusano, B. M. Sadler, J.
Millard, W. T. Symonds, M. Tisdale, C. Rawls, A. Bye, and the
141W94 International Product Development Team, Abstr.
37th Intersci. Conf. Antimicrob. Agents Chemother., abstr
A-16, 1997; D. S. Stein, Y. Lou, M. Johnson, and S. Randall for
the PROB2004 Study Team, Abstr. 2nd Int. Workshop Clin.
Pharmacol. HIV Ther., no. 5.6, 2001); therefore, the lower
amprenavir AUCss observed with the amprenavir-saquinavir
sgc regimen could theoretically lead to reduced antiretroviral
efficacy and/or the development of resistance. It is not possible
to definitely attribute the decrease to an amprenavir-saquina-
vir sgc interaction, since food was a potential confounding
factor. All amprenavir-saquinavir sgc doses were given with
food in this study, and the pharmacokinetics of the currently
marketed amprenavir formulation (150-mg capsule) have been
noted to be modestly affected by a high-fat meal, resulting in
decreased amprenavir concentrations of approximately 25%
(Glaxo Wellcome, complete prescribing information for am-
prenavir [Agenerase]).
The significant increase in amprenavir Cmin,ss (189% or 2.9-
fold) produced by nelfinavir was not accompanied by such a
large increase in Cmax,ss or AUCss. Amprenavir Cmax,ss actually
decreased, although not significantly, with nelfinavir coadmin-
istration; however, as discussed above, this could have been
confounded by a possible food effect. The large increase in
amprenavir Cmin,ss could result in heightened antiviral activity,
but longer-term evaluations of efficacy and safety are needed
to determine whether this is indeed true. These changes in
amprenavir concentrations produced by nelfinavir could result
from a complex interaction of binding to plasma proteins—
both amprenavir and nelfinavir are highly bound to the same
plasma proteins, AAG and albumin—or to changes in distri-
bution and/or metabolism. Another small study has also indi-
cated a effect similar to what we observed from nelfinavir
coadministration on amprenavir pharmacokinetics (S. Pis-
citelli, C. Bechtel, B. Sadler, and J. Falloon, 7th Conf. Retro-
viruses Opportunistic Infect., abstr. 78, 2000).
Indinavir coadministration (in the fasting condition, in con-
trast to the other two partner protease inhibitors) produced
only a 33% increase in amprenavir AUCss. This finding, when
considered together with an 18% increase in Cmax,ss and a 25%
increase in Cmin,ss, suggests that these changes in plasma am-
prenavir concentrations are unlikely to be clinically relevant.
The nelfinavir and saquinavir sgc steady-state pharmacokinetic
parameters obtained in this study were not different from those
previously reported for nelfinavir alone and saquinavir sgc
alone, as indicated by the finding that the historical reference
values were within the range of the 95% CI of the means of the
parameters obtained in this study (Table 2). However, al-
though amprenavir coadministration did not have an effect on
nelfinavir or saquinavir sgc steady-state pharmacokinetic pa-
rameters, amprenavir coadministration did appear to affect
indinavir Cmax,ss, Cmin,ss, AUCss, and CL/F compared with
historical data. Amprenavir coadministration resulted in a de-
crease in indinavir Cmax,ss, Cmin,ss, and AUCss and an increase
in indinavir CL/F. These changes are not due to induction of
hepatic metabolism or P-glycoprotein transport, since a single
dose of amprenavir in the same patients had a similar effect on
indinavir pharmacokinetics. A possible explanation for the ob-
served decreases is the lipid-like formulation of amprenavir,
which could affect indinavir pharmacokinetics in a manner
similar to that of a food effect. It has been previously reported
that a high-calorie, high-fat meal significantly decreases indi-
navir Cmax and AUC by 86 and 78%, respectively (24).
The statistical analysis of the relationship between various
fixed effects (such as AAG, age, albumin, and race) and am-
prenavir pharmacokinetic parameters revealed that the coad-
ministered protease inhibitor treatment and AAG levels were
the only variables that significantly influenced amprenavir
pharmacokinetics. After controlling for AAG concentrations,
no statistically significant difference in amprenavir AUCss,
Cmax,ss, Cmin,ss, and CL/F was noted between blacks (n 
 11)
and nonblacks (n 
 23). Gender was not evaluated because
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two treatment groups had only one female each. The finding of
a significant treatment effect by the partner protease inhibitor
indicates that each of the protease inhibitors had different
effects on amprenavir steady-state pharmacokinetics. AAG
concentrations were significantly correlated with amprenavir
steady-state pharmacokinetics. Decreasing AAG concentra-
tions, as would occur with suppressive HIV therapy, were as-
sociated with decreasing total concentrations of amprenavir
(i.e., protein-bound and unbound drug). Like most HIV pro-
tease inhibitors, amprenavir exhibits a high degree of high-
affinity binding to AAG (90%) (12). Changes in AAG, while
affecting the measured total amprenavir concentration, are not
believed to affect the unbound amprenavir concentration, since
clearance of unbound drug (i.e., intrinsic clearance) is un-
changed (20).
The present study was designed to evaluate the pharmaco-
kinetics and short-term safety of multiple-dose, dual protease
inhibitor therapy in protease inhibitor-naı̈ve, HIV-infected
subjects. Steady-state pharmacokinetic data for all four pro-
tease inhibitors in the three dual protease inhibitor combina-
tions obtained in this study indicate that no drug interactions
preclude the use of any of the combinations and suggest that
further investigation of the dual protease inhibitor regimens as
an antiretroviral therapy strategy is warranted. The results of
this study have supported continued treatment of these sub-
jects in the phase I-II follow-on of this study to evaluate longer-
term safety and efficacy of the amprenavir-containing dual
HIV protease inhibitor regimens.
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